This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor(Laverdia-CA1). We will review SINE mechanism of actionalong with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval ofLaverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor their lymphoma patient on verdinexor, including how to address any potential adverse events.
- How SINE drugs work and why they are different
- When to consider treatment with verdinexor
- How to administer verdinexor
- Verdinexor side effect profile and appropriate treatment options
- Safe handling guidelines for verdinexor
Canine
Presented by Philip J. Bergman, Director, Clinical Studies - Mars Veterinary Health & VCA
Presented at New York Vet 2024